Crossmark

Letter to the Editor Regarding ‘Levodopa Intestinal Gel Infusion Therapies in Advanced Parkinson's Disease: A Swedish Study on Real-World Use and Costs’

Crossref DOI link: https://doi.org/10.1007/s40120-025-00875-y

Published Online: 2025-12-23

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Smith, Niall https://orcid.org/0009-0000-1419-4094
Funding

Funding for this research was provided by:

Britannia Pharmaceuticals
License Information

Text and Data Mining valid from 2025-12-23

Version of Record valid from 2025-12-23
More Information

Article History

Received: 4 August 2025

Accepted: 2 December 2025

First Online: 23 December 2025

Declarations

:

: Niall Smith is an employee of Britannia Pharmaceuticals Ltd.

: This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by the author.

Document is current

Any future updates will be listed below